DK2070526T3 - Fremgangsmåder til behandling af parkinsons sygdom - Google Patents
Fremgangsmåder til behandling af parkinsons sygdomInfo
- Publication number
- DK2070526T3 DK2070526T3 DK09154864.4T DK09154864T DK2070526T3 DK 2070526 T3 DK2070526 T3 DK 2070526T3 DK 09154864 T DK09154864 T DK 09154864T DK 2070526 T3 DK2070526 T3 DK 2070526T3
- Authority
- DK
- Denmark
- Prior art keywords
- disease
- methods
- treating parkinson
- parkinson
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46220503P | 2003-04-11 | 2003-04-11 | |
EP04726590A EP1613296B1 (en) | 2003-04-11 | 2004-04-08 | Methods for treatment of parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2070526T3 true DK2070526T3 (da) | 2014-03-24 |
Family
ID=33159845
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04726590T DK1613296T3 (da) | 2003-04-11 | 2004-04-08 | Fremgangsmåder til behandling af Parkinsons sygdom |
DK09154864.4T DK2070526T3 (da) | 2003-04-11 | 2004-04-08 | Fremgangsmåder til behandling af parkinsons sygdom |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04726590T DK1613296T3 (da) | 2003-04-11 | 2004-04-08 | Fremgangsmåder til behandling af Parkinsons sygdom |
Country Status (28)
Country | Link |
---|---|
US (3) | US8283380B2 (da) |
EP (2) | EP1613296B1 (da) |
JP (2) | JP2006522800A (da) |
KR (2) | KR20110070929A (da) |
CN (2) | CN102274517B (da) |
AR (1) | AR044007A1 (da) |
AT (1) | ATE435012T1 (da) |
AU (1) | AU2004228782B2 (da) |
BR (1) | BRPI0409364A (da) |
CA (1) | CA2523188C (da) |
CY (3) | CY1109295T1 (da) |
DE (1) | DE602004021790D1 (da) |
DK (2) | DK1613296T3 (da) |
ES (2) | ES2326373T3 (da) |
FR (1) | FR15C0054I2 (da) |
HU (1) | HUS1500043I1 (da) |
IL (2) | IL171331A (da) |
LU (1) | LU92782I2 (da) |
MX (1) | MXPA05010873A (da) |
NL (1) | NL300752I2 (da) |
NO (3) | NO334316B1 (da) |
NZ (1) | NZ542910A (da) |
PL (2) | PL1613296T3 (da) |
PT (2) | PT1613296E (da) |
RU (1) | RU2342929C2 (da) |
SI (2) | SI1613296T1 (da) |
TW (1) | TWI340640B (da) |
WO (1) | WO2004089353A2 (da) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
EP1423168B1 (en) * | 2001-09-03 | 2006-02-08 | Newron Pharmaceuticals S.p.A. | Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use |
EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
ES2339021T3 (es) * | 2003-08-25 | 2010-05-14 | Newron Pharmaceuticals S.P.A. | Derivados de alfa-aminoamida utiles como agentes antiinflamatorios. |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
AU2005282028B2 (en) * | 2004-09-10 | 2011-03-24 | Newron Pharmaceuticals S.P.A. | (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
US20070004639A1 (en) * | 2005-07-01 | 2007-01-04 | Bodybio, Inc. | Methods and compositions for treating Parkinson's disease |
EP1954256A2 (en) * | 2005-11-09 | 2008-08-13 | Torrent Pharmaceuticals Ltd | Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent |
NZ567540A (en) * | 2005-12-22 | 2010-07-30 | Newron Pharm Spa | 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators |
CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
EP1870097A1 (en) * | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
US8106056B2 (en) * | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
DK2474521T3 (da) * | 2006-06-19 | 2016-10-31 | Newron Pharm Spa | Højrene 2-[4-(3- and 2-fluorbenzyloxy)benzylamino]propanamider til anvendelse som lægemidler og farmaceutiske formuleringer dermed |
DE102007014947B4 (de) * | 2007-03-23 | 2010-05-27 | Axxonis Pharma Ag | Stabilisierte wässrige Lösungen von Ergolinverbindungen |
JP2010525018A (ja) * | 2007-04-24 | 2010-07-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物 |
DK2155663T3 (da) | 2007-06-15 | 2018-01-22 | Newron Pharm Spa | Substituerede 2-[2-(phenyl)ethylamino]alkanamidderivater og deres anvendelse som natrium- og/eller kalciumkanalmodulatorer |
GB2453770A (en) * | 2007-10-19 | 2009-04-22 | Reckitt Benckiser Healthcare | Oral composition comprising a cooling agent |
US20090149544A1 (en) * | 2007-10-22 | 2009-06-11 | Concert Pharmaceuticals, Inc. | Alpha-aminoamide derivatives |
BRPI0820657A2 (pt) | 2007-12-11 | 2015-06-16 | Newron Pharm Spa | Processo para a produção de 2-[4-(3- ou 2-fluorobenzilóxi)benzilamino]pro-panamidas com alto grau de pureza |
AU2008340552B2 (en) * | 2007-12-19 | 2013-08-22 | Newron Pharmaceuticals S.P.A. | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders |
WO2009122351A2 (en) * | 2008-04-01 | 2009-10-08 | Kangwon National University | Anti-parkinsonian compounds mppe |
WO2009147430A1 (en) * | 2008-06-02 | 2009-12-10 | Generics [Uk] Limited | A process for the preparation of enantiomerically pure amines |
CN102203053B (zh) * | 2008-06-02 | 2015-11-25 | 基因里克斯(英国)有限公司 | 用于制备胺的改进方法 |
RU2540470C9 (ru) * | 2008-06-06 | 2015-07-20 | Фарма Ту Б Лтд. | Фармацевтические композиции для лечения болезни паркинсона |
BRPI0909894A2 (pt) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica. |
WO2010010138A1 (en) * | 2008-07-24 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease |
US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
EP2218444A3 (en) * | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
EP2314569A1 (en) | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
CN102048717B (zh) | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
WO2011098456A1 (en) | 2010-02-09 | 2011-08-18 | Merck Serono S.A. | Safinamide in the treatment of dyskinesia |
AU2011246707B2 (en) | 2010-04-27 | 2014-11-20 | Newron Pharmaceuticals S.P.A. | Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers |
UA103851C2 (en) | 2010-04-30 | 2013-11-25 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Propylaminoindan transdermal composition |
WO2012129429A2 (en) | 2011-03-24 | 2012-09-27 | Teikoku Pharma Usa, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
CA2845854A1 (en) | 2011-08-19 | 2013-02-28 | The Trustees Of Princeton University | C-halogen bond formation |
US20150031768A1 (en) * | 2011-08-19 | 2015-01-29 | The Trustees Of Princeton University | C-halogen bond formation |
JP5913614B2 (ja) | 2011-11-09 | 2016-04-27 | テイコク ファーマ ユーエスエー インコーポレーテッド | 皮膚新生物の処置方法 |
WO2014070622A1 (en) | 2012-11-02 | 2014-05-08 | Teikoku Pharma Usa, Inc. | Propynylaminoindan transdermal compositions |
US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
KR20160026897A (ko) * | 2013-06-27 | 2016-03-09 | 세다르스-신나이 메디칼 센터 | 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제 |
US20170296498A1 (en) * | 2014-04-21 | 2017-10-19 | Civitas Therapeutics, Inc. | Rapid Relief of Motor Fluctuations in Parkinson's Disease |
US10676425B2 (en) | 2014-10-02 | 2020-06-09 | Megabiowood Co., Ltd | Alpha-aminoamide derivative compound and pharmaceutical composition comprising same |
HUE047531T2 (hu) * | 2015-08-27 | 2020-04-28 | Prexton Therapeutics Sa | Levodopa indukálta diszkinézia kezelésére alkalmas, agyba bejutni képes kromon oxim-származék |
KR20230038214A (ko) * | 2016-03-17 | 2023-03-17 | 더 존스 홉킨스 유니버시티 | Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법 |
ITUA20163981A1 (it) | 2016-05-31 | 2017-12-01 | Zambon Spa | Composizioni farmaceutiche comprendenti safinamide |
WO2018132746A1 (en) * | 2017-01-14 | 2018-07-19 | Mischley Laurie Kathern | Method of using human excrement and secretions for early detection of parkinson's disease |
CN109251155A (zh) * | 2017-07-14 | 2019-01-22 | 广东东阳光药业有限公司 | α-氨基酰胺衍生物及其用途 |
CA3072994A1 (en) * | 2017-08-17 | 2019-02-21 | Zi-Qiang Gu | Pamoate salt of monoamine anti-parkinson's agents, method of preparation and use thereof |
AU2018357886B2 (en) | 2017-11-02 | 2024-04-18 | Zambon S.P.A. | Pharmaceutical compositions comprising safinamide |
KR102005019B1 (ko) * | 2018-04-04 | 2019-07-31 | 한국과학기술연구원 | 뇌졸중의 예방 및 치료용 조성물 |
CN110938014A (zh) * | 2019-11-28 | 2020-03-31 | 岳千奥 | 取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物 |
EP4070793A4 (en) * | 2019-12-06 | 2023-06-14 | Shanghai Pharmaceuticals Holding Co., Ltd. | PHARMACEUTICAL COMPOSITION, COMPLEMENTARY KIT AND ITS APPLICATION |
CN110999980A (zh) * | 2019-12-19 | 2020-04-14 | 新疆石河子职业技术学院(石河子市技工学校) | 一种葡萄酒洗浸奶酪加工方法 |
US20230181508A1 (en) * | 2020-08-31 | 2023-06-15 | Purdue Pharma L.P. | Compositions and methods for levodopa delivery |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1140748A (en) | 1966-06-23 | 1969-01-22 | Ici Ltd | New carboxylic acid derivatives |
US3795739A (en) * | 1972-02-14 | 1974-03-05 | Hoffmann La Roche | Treatment of parkinson disease |
US4049663A (en) | 1972-06-06 | 1977-09-20 | Allen & Hanburys Limited | Ethylene diamine derivatives |
FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
US4935429A (en) | 1985-10-25 | 1990-06-19 | Dackis Charles A | Method of treating psychostimulant addiction |
ATE76747T1 (de) * | 1986-06-10 | 1992-06-15 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
CA1336169C (en) | 1988-03-01 | 1995-07-04 | Walther Birkmayer | Agent for treatment of parkinson's disease |
IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5502658A (en) | 1990-12-27 | 1996-03-26 | Relin; Arkadi | Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity |
GB9306886D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
RU2176145C2 (ru) * | 1995-05-26 | 2001-11-27 | Пфайзер Инк. | Синергическое лечение паркинсонизма |
GB9515412D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
US20020019421A1 (en) * | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
FR2829027A1 (fr) * | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
-
2004
- 2004-04-07 AR ARP040101189A patent/AR044007A1/es unknown
- 2004-04-08 PL PL04726590T patent/PL1613296T3/pl unknown
- 2004-04-08 DE DE602004021790T patent/DE602004021790D1/de not_active Expired - Lifetime
- 2004-04-08 PL PL09154864T patent/PL2070526T3/pl unknown
- 2004-04-08 BR BRPI0409364-0A patent/BRPI0409364A/pt not_active Application Discontinuation
- 2004-04-08 MX MXPA05010873A patent/MXPA05010873A/es active IP Right Grant
- 2004-04-08 CN CN201110271872.8A patent/CN102274517B/zh not_active Expired - Lifetime
- 2004-04-08 CN CNA200480009655XA patent/CN1771030A/zh active Pending
- 2004-04-08 PT PT04726590T patent/PT1613296E/pt unknown
- 2004-04-08 JP JP2006506582A patent/JP2006522800A/ja active Pending
- 2004-04-08 PT PT91548644T patent/PT2070526E/pt unknown
- 2004-04-08 EP EP04726590A patent/EP1613296B1/en not_active Expired - Lifetime
- 2004-04-08 AU AU2004228782A patent/AU2004228782B2/en not_active Expired
- 2004-04-08 US US10/559,982 patent/US8283380B2/en active Active
- 2004-04-08 AT AT04726590T patent/ATE435012T1/de active
- 2004-04-08 EP EP09154864.4A patent/EP2070526B1/en not_active Expired - Lifetime
- 2004-04-08 WO PCT/IB2004/001408 patent/WO2004089353A2/en active Application Filing
- 2004-04-08 TW TW093109755A patent/TWI340640B/zh active
- 2004-04-08 DK DK04726590T patent/DK1613296T3/da active
- 2004-04-08 ES ES04726590T patent/ES2326373T3/es not_active Expired - Lifetime
- 2004-04-08 CA CA2523188A patent/CA2523188C/en not_active Expired - Lifetime
- 2004-04-08 SI SI200431192T patent/SI1613296T1/sl unknown
- 2004-04-08 RU RU2005131422/15A patent/RU2342929C2/ru active
- 2004-04-08 SI SI200432150T patent/SI2070526T1/sl unknown
- 2004-04-08 KR KR1020117013555A patent/KR20110070929A/ko not_active Application Discontinuation
- 2004-04-08 DK DK09154864.4T patent/DK2070526T3/da active
- 2004-04-08 NZ NZ542910A patent/NZ542910A/en unknown
- 2004-04-08 ES ES09154864.4T patent/ES2454272T3/es not_active Expired - Lifetime
- 2004-04-08 KR KR1020057019264A patent/KR101129015B1/ko active Protection Beyond IP Right Term
-
2005
- 2005-10-10 NO NO20054640A patent/NO334316B1/no active Protection Beyond IP Right Term
- 2005-10-10 IL IL171331A patent/IL171331A/en active Protection Beyond IP Right Term
-
2009
- 2009-08-12 CY CY20091100857T patent/CY1109295T1/el unknown
-
2011
- 2011-11-17 IL IL216403A patent/IL216403A/en active IP Right Grant
-
2012
- 2012-08-24 US US13/594,621 patent/US8901176B2/en not_active Expired - Lifetime
- 2012-12-14 JP JP2012273371A patent/JP2013067647A/ja active Pending
-
2013
- 2013-10-28 NO NO20131417A patent/NO335537B1/no unknown
-
2014
- 2014-04-15 CY CY20141100288T patent/CY1115286T1/el unknown
- 2014-11-04 US US14/532,925 patent/US9492410B2/en not_active Expired - Lifetime
-
2015
- 2015-07-01 CY CY2015025C patent/CY2015025I2/el unknown
- 2015-07-17 NL NL300752C patent/NL300752I2/nl unknown
- 2015-07-22 HU HUS1500043C patent/HUS1500043I1/hu unknown
- 2015-07-22 LU LU92782C patent/LU92782I2/xx unknown
- 2015-07-22 FR FR15C0054C patent/FR15C0054I2/fr active Active
- 2015-07-23 NO NO2015018C patent/NO2015018I1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1613296T3 (da) | Fremgangsmåder til behandling af Parkinsons sygdom | |
DK1443955T3 (da) | PDGF-BB til behandling af Parkinsons sygdom | |
DK1620437T3 (da) | 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension | |
DE602004006169D1 (de) | Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate | |
DK1720571T3 (da) | Fremgangsmåde til behandling af hæmolytisk sygdom | |
DK1997512T3 (da) | Fremgangsmåder til behandling af TWEAK-relaterede tilstande | |
DK2821085T3 (da) | Rna-interferens til behandling af "gain-of-function"-forstyrrelser | |
DE602004019373D1 (de) | Bilderzeugungsverfahren | |
DK1575597T3 (da) | Anvendelse af rimexolon til behandling af öjentörhed | |
DE602004002056D1 (de) | Fixation d'un coussin gonflable | |
DE602004000916D1 (de) | Rückkopplungsgeregeltes Spannsystem | |
DK1628988T3 (da) | Hidtil ukendte 14- og 15 leddede ringforbindelser | |
FR2851326B3 (fr) | Hotte d'extraction | |
DK1639139T3 (da) | Fremgangsmåder til påvisning af Alzheimers sygdom | |
DK1699747T3 (da) | Fremgangsmåde til fremstilling af 2,3-cis-substitueret 2-arylpropenaler | |
FR2892012B1 (fr) | Procede d'epilation | |
FR2852042B1 (fr) | Piece d'aretier | |
DE50209339D1 (de) | Kalander | |
ES1054316Y (es) | "forjado nervado" | |
SE0201072D0 (sv) | Homing process | |
NO20033536D0 (no) | Snus-porsjonerer | |
ITPT20030007U1 (it) | "mybox" | |
FI5888U1 (fi) | Kalanteri | |
ITRC20030003U1 (it) | "portamonete" | |
ES1054594Y (es) | "termostato perfeccionado" |